MAMariana Araújo

Mariana Araújo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Araújo has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Maria Miragaia

    Laboratory of Bacterial Evolution and Molecular Epidemiology, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa (ITQB-NOVA), Oeiras, Portugal

    2 shared publications
  • Nuno Alexandre Faria

    Laboratory of Bacterial Evolution and Molecular Epidemiology, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa

    2 shared publications
  • Ana Botelho

    Laboratory of Bacterial Evolution and Molecular Epidemiology, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal

    1 shared publication
  • Beatriz Royo

    Instituto de Tecnologia Química e Biológica António Xavier ITQB NOVA Universidade Nova de Lisboa Oeiras Portugal

    1 shared publication
  • Cláudia Malta-Luís

    Instituto de Tecnología Química e Biológica António Xavier, Universidade Nova de Lisboa

    1 shared publication
  • Diana Caieiro

    Laboratory of Bacterial Evolution and Molecular Epidemiology, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal

    1 shared publication

Latest Publications

  • Open Access

    In Vitro Activity of a Novel Metal-Based Antimicrobial against Multidrug-Resistant Klebsiella pneumoniae

    by Raquel L. Almeida, Nuno A. Faria, Mariana Araújo, Cláudia Malta-Luís, Francisco C. Mendes, Oscar Lenis-Rojas, Beatriz Royo, Maria Miragaia

    Multidrug-resistant (MDR) Klebsiella pneumoniae , classified by the World Health Organization (WHO) as a critical priority pathogen, represents a global health thereat requiring novel antimicrobials urgently. Here we evaluated the in vitro antimicrobial activity of a novel iridium-based compound (OMKP-3), against MDR K. pneumoniae . OMKP-3 exhibited robust antimicrobial activity in M9 minimal media (MIC=6.25µg/mL) and rapid bactericidal effect (MBC=12.5µg/mL) against the tested MDR K. pneumoniae strains. OMKP-3 showed antibiofilm ability and was active against multiple MDR Gram-negative pathogens, including Escherichia coli , Enterobacter cloacae , Pseudomonas aeruginosa and Serratia marcescens (MIC range:6.25-25µg/mL). Importantly, OMKP-3 showed no cytotoxicity against mammalian cells after 24 hours of exposure. When combined with polymyxin B, OMKP-3 acted as an adjuvant, enhancing polymyxin B activity (FIC≤0.5). OMKP-3 was less prone to induce high-level resistance in MDR K. pneumoniae compared to ciprofloxacin, and supressed the growth of resistant bacteria at a low and non-cytotoxic concentration (4xMIC). K. pneumoniae strains harboring truncated Ompk35/36 porin genes exhibited higher OMKP-3 MICs, indicating that these porins may serve as an important entry pathway. Spectrometry analysis revealed that OMKP-3 was able to accumulate intracellularly (1.57µg/mL), with minimal Resistance-Nodulation-Division (RND) efflux pump extrusion involvement. Furthermore, analysis of the resistant mutant, harboring a mutation in the outer membrane protein DegS, together with fluorescence microscopy, suggests that OMKP-3 induces membrane-associated damage. No cross-resistance between OMKP-3 and commonly used antibiotics was observed. Collectively, these findings identify OMKP-3 as a promising novel antimicrobial agent against MDR K. pneumoniae , likely acting through an unexplored bacterial target. Importance: Multidrug-resistant (MDR) Klebsiella pneumoniae is a critical global health threat and is among the leading causes of hospital0hyphenorendash;associated mortality, largely due to the scarcity of effective therapeutic options. Alarmingly, the current antimicrobial pipeline fails to address this issue, relying largely on derivatives of existing scaffolds that offer only short-term clinical benefit due to rapid resistance emergence. Developing antibiotics against Gram-negative pathogens is particularly challenging because of their highly impermeable outer membrane and efficient efflux systems, limiting intracellular drug accumulation. Metal-based antimicrobials emerge as a promising alternative. Our findings showed that OMKP-3, an iridium complex, exhibits potent bactericidal activity against MDR K. pneumoniae without selecting for high-level resistance, suggesting the potential for sustained therapeutic efficacy. Additionally, it demonstrated to accumulate intracellularly with minimal efflux involvement. Together, these features position OMKP-3 as a valuable and underexplored novel antimicrobial strategy for addressing the escalating threat of MDR K. pneumoniae infections.

  • Open Access

    Methicillin-Susceptible Staphylococcus aureus ST398 in atopic dermatitis in Portugal displays pathogenic traits associated with impaired skin barrier function

    by Diana Caieiro, Nuno A. Faria, Ana Botelho, Mariana Araújo, Leonor Ramos, Joana Calvão, Margarida Gonçalo, Maria Miragaia

    Staphylococcus aureus plays a central role in the exacerbation of atopic dermatitis (AD), but the population structure and pathogenic determinants of strains colonizing AD patients remain poorly understood. It is unclear whether these strains mirror those circulating in the general community or whether specific clonal lineages are selectively adapted to the AD skin microenvironment. Data addressing this question are scarce, particularly in Portugal. In this study, we investigated the molecular epidemiology and pathogenic traits of S. aureus colonizing skin lesions in adult patients with AD in Portugal. We found that lesion-associated isolates belonged predominantly to the methicillin-susceptible S. aureus MSSA-ST398 clonal type, a lineage that is widely circulating in the Portuguese community, particularly among vulnerable populations, and that has also been implicated in severe human infections. Notably, isolates from this clonal type in AD harboured specific pathogenicity traits associated with skin barrier disruption, including hemolysin and urease production, which may contribute to their success as colonizers in AD. Our findings highlight that S. aureus colonization in AD arises from a dynamic interplay between community-level molecular epidemiology and disease-specific selective pressures. While circulating lineages provide the genetic background diversity, the AD skin microenvironment appears to shape which clones ultimately become dominant. Such an integrated perspective may help to inform future geographically tailored strategies aimed at limiting bacterial burden and preventing disease exacerbation in AD.